Phase trial fluorouracil modulation N-phosphonacetyl-L-aspartate riboside optimization riboside dose schedule biochemical analysis sequential tumor biopsy specimens Preclinical clinical studies selective antitumor activity fluorouracil agents certain intracellular nucleotide pools combination N-phosphonacetyl-L-aspartate PALA pyrimidine nucleotide pools response rate assessable patients colorectal carcinoma preclinical tumor models riboside MMPR inhibitor purine synthesis phosphoribosylpyrophosphate PRPP pools anabolism nucleotides vivo addition MMPR therapeutic efficacy phase trial optimal dose schedule MMPR combination PALA day infusion day MMPR day patients solid tumors colorectal breast Toxic effects mild leukopenia mucositis nausea rash patients MMPR diarrhea PRPP orotic acid release assay tumor biopsy specimens hours hours MMPR doses patients addition MMPR PRPP pools human solid tumors hours treatment patients twofold elevation PRPP MMPR dose level similar elevation patients MMPR patients MMPR hours treatment results respective dose levels MMPR patients patients patients Administration dose levels increase tumor PRPP levels toxicity dose level dose level Tumor levels PRPP hours hours patients time course MMPR beginning infusion 